Day: August 27, 2020

IRVING, Texas, Aug. 27, 2020 (GLOBE NEWSWIRE) — LexiCode, an Exela Technologies, Inc. (“Exela”) (NASDAQ: XELA) brand, today announced the availability of its LexiCode Audit Database (LAD) analytics tool, a web-based solution created to add value and efficiency to LexiCode’s audit process. As data is entered in real time, the system continuously monitors and creates accuracy ratings to increase quality and transparency by tracking all elements of the coding process. The solution serves as a differentiator for LexiCode in the coding process by automating the accuracy calculations in addition to generating daily feedback summaries for the coders.The solution takes the audit trail a step further than coding by helping the audit team determine what errors are occurring, what pain points clients are experiencing, and allowing LexiCode...

Nasdaq First North Growth MarketSelskabsmeddelelse nr. 21/2020                                                                  Odense, 27. august 2020 Scape Technologies A/S halvårsresultat 2020 Bestyrelsen i Scape Technologies A/S har i dag godkendt det ikke-reviderede halvårsregnskab for 2020.Halvårets resultater i sammendrag Regnskabet er stærkt præget af den midlertidige tilbagegang hos kunderne i bilindustrien p.g.a. Covid-19 og viser et fald i omsætningen i første halvår 2020 til 0,9 millioner kroner. Driftsunderskuddet er på 11,8 millioner kroner efter skat mod 6,9 millioner kroner efter skat i første halvår 2019.Scape Technologies har i første halvår 2020 primært haft fokus på eksekveringen af forretningsstrategien med særlig vægt på den produktudvikling, der skal højne brugervenligheden og forenkle konfigurering, salg, installation...

PLANO, Texas, Aug. 27, 2020 (GLOBE NEWSWIRE) — DZS (NSDQ: DZSI), a leading enabler of the hyper-connected world, today announced that Charlie Vogt, DZS President and CEO, and Thomas Cancro, DZS Chief Financial Officer, are scheduled to participate in the Jefferies Virtual Semiconductor, IT Hardware and Communications Infrastructure Summit on September 1, 2020. Virtual 1×1 meetings will be held from 7:50am-6:40pm (ET).About DZSDZS Inc. (NSDQ: DZSI or “DZS”) is a global provider of leading-edge access, 5G transport, and enterprise communications platforms that enable the hyper-connected world. Over 1200 service providers, operators, and enterprises in over 120 countries have leveraged DZS innovation, open solutions, and agility to arm them with the network resources and deployment freedom they need to lead in their markets and...

Testing Validates InvisibleShield Solutions with Integrated Kastus Anti-Microbial Technology Kills Human Coronavirus and 99.99% of the Most Common Surface BacteriaSALT LAKE CITY, Aug. 27, 2020 (GLOBE NEWSWIRE) — InvisibleShield®, a ZAGG Brands (NASDAQ:ZAGG) company and the leading global innovator in screen protection, today announced that its 2020 screen protectors treated with exclusive partner Kastus® anti-microbial technology have been examined by an independent global testing laboratory and confirmed effective against human coronavirus and 99.99% of the most common surface bacteria1. In a study published in the New England Journal of Medicine, researchers found that human coronavirus can live on surfaces for up to three days2.With Kastus technology, InvisibleShield customers now have the additional assurance that their device...

CALGARY, Alberta, Aug. 27, 2020 (GLOBE NEWSWIRE) — Gibson Energy Inc. (“Gibson” or the “Company”), (TSX: GEI), announced today the initiation of a Normal Course Issuer Bid (“NCIB”).Gibson’s Board of Directors has approved a NCIB, and the Toronto Stock Exchange (the “TSX”) has accepted Gibson’s Notice of Intention to Make a NCIB, enabling the Company to purchase and cancel up to 10%, or 11,765,180, of the public float for the issued and outstanding common shares as of August 24, 2020 over the next 12 months commencing August 31, 2020 in accordance with the applicable rules and policies of the TSX and applicable securities laws. Under the NCIB, common shares may be repurchased in open market transactions on the TSX, and/or other Canadian alternative trading platforms. In accordance with the rules of the TSX governing a NCIB, the total...

WINNIPEG, Manitoba, Aug. 27, 2020 (GLOBE NEWSWIRE) — DELTA 9 CANNABIS INC. (TSX: DN) (OTCQX: VRNDF) (“Delta 9” or the “Company”), is pleased to announce that it has amended the Company’s credit facilities (the “Credit Facilities”) with Canadian Western Bank (the “Bank”) with the addition of new loan segments and amendments to certain existing loan segments. The amendments bring the Company’s total Credit Facilities with the Bank to approximately $22 Million and increase the company’s cash position by $5.4 Million.“Delta 9 is one of the only cannabis operators in Canada that have been successful at accessing conventional credit facilities with a Tier 1 chartered bank,” said Delta 9 CEO, John Arbuthnot. “This additional cash, together with working capital of $24.5 Million and $6.0 Million in cash as of...

Sustained anti-cholestatic and hepatoprotective effects observed in patients with and without cirrhosisSelf-reported pruritus improved at one year for patients in highest categories of baseline itchSelected for inclusion in the “Best of ILC” presentationResults mirror recently reported ENHANCE Phase 3 data confirming anti-cholestatic and anti-pruritic effects of seladelparNEWARK, Calif., Aug. 27, 2020 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced final results from a previously completed open-label Phase 2 study of seladelpar in patients with primary biliary cholangitis (PBC). These data will be made available as an electronic presentation through the Digital...

SOUTH SAN FRANCISCO, Calif., Aug. 27, 2020 (GLOBE NEWSWIRE) — Applied Molecular Transport (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that the first patient has been dosed in a randomized, placebo-controlled, double-blind, multicenter Phase 2a study evaluating the efficacy and safety of oral AMT-101 in patients with moderate to severely active ulcerative colitis (UC). AMT-101 is a gut-selective, oral, once-daily, biologic fusion protein of interleukin 10 (IL-10) which utilizes the company’s proprietary platform technology to harness the power of natural active transport mechanisms for a potentially more efficacious and safer biologic therapeutic.“We are pleased with the speed at which we have launched this first Phase 2 clinical trial for AMT 101 in biologic-naïve and treatment-experienced UC...